AU2017244114B2 - Novel compositions and therapeutic methods - Google Patents

Novel compositions and therapeutic methods Download PDF

Info

Publication number
AU2017244114B2
AU2017244114B2 AU2017244114A AU2017244114A AU2017244114B2 AU 2017244114 B2 AU2017244114 B2 AU 2017244114B2 AU 2017244114 A AU2017244114 A AU 2017244114A AU 2017244114 A AU2017244114 A AU 2017244114A AU 2017244114 B2 AU2017244114 B2 AU 2017244114B2
Authority
AU
Australia
Prior art keywords
compounds
compound
patient
formula
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017244114A
Other languages
English (en)
Other versions
AU2017244114A1 (en
Inventor
Suchismita ACHARYA
Beamon Agarwal
Pragnya DAS
Santosh K. Panda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ayuvis Research Inc
Original Assignee
Ayuvis Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ayuvis Research Inc filed Critical Ayuvis Research Inc
Publication of AU2017244114A1 publication Critical patent/AU2017244114A1/en
Application granted granted Critical
Publication of AU2017244114B2 publication Critical patent/AU2017244114B2/en
Priority to AU2021232715A priority Critical patent/AU2021232715A1/en
Priority to AU2023222844A priority patent/AU2023222844A1/en
Priority to AU2025205307A priority patent/AU2025205307A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017244114A 2016-03-30 2017-03-30 Novel compositions and therapeutic methods Active AU2017244114B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2021232715A AU2021232715A1 (en) 2016-03-30 2021-09-15 Novel compositions and therapeutic methods
AU2023222844A AU2023222844A1 (en) 2016-03-30 2023-08-29 Novel compositions and therapeutic methods
AU2025205307A AU2025205307A1 (en) 2016-03-30 2025-07-09 Novel compositions and therapeutic methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662315144P 2016-03-30 2016-03-30
US62/315,144 2016-03-30
PCT/US2017/024908 WO2017173024A1 (en) 2016-03-30 2017-03-30 Novel compositions and therapeutic methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021232715A Division AU2021232715A1 (en) 2016-03-30 2021-09-15 Novel compositions and therapeutic methods

Publications (2)

Publication Number Publication Date
AU2017244114A1 AU2017244114A1 (en) 2018-11-08
AU2017244114B2 true AU2017244114B2 (en) 2021-07-22

Family

ID=59958482

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2017244114A Active AU2017244114B2 (en) 2016-03-30 2017-03-30 Novel compositions and therapeutic methods
AU2021232715A Abandoned AU2021232715A1 (en) 2016-03-30 2021-09-15 Novel compositions and therapeutic methods
AU2023222844A Abandoned AU2023222844A1 (en) 2016-03-30 2023-08-29 Novel compositions and therapeutic methods
AU2025205307A Pending AU2025205307A1 (en) 2016-03-30 2025-07-09 Novel compositions and therapeutic methods

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2021232715A Abandoned AU2021232715A1 (en) 2016-03-30 2021-09-15 Novel compositions and therapeutic methods
AU2023222844A Abandoned AU2023222844A1 (en) 2016-03-30 2023-08-29 Novel compositions and therapeutic methods
AU2025205307A Pending AU2025205307A1 (en) 2016-03-30 2025-07-09 Novel compositions and therapeutic methods

Country Status (10)

Country Link
US (1) US11207343B2 (https=)
EP (1) EP3436467B1 (https=)
JP (5) JP2019513137A (https=)
KR (2) KR102306956B1 (https=)
CN (2) CN114712383B (https=)
AU (4) AU2017244114B2 (https=)
BR (1) BR112018067833B1 (https=)
CA (2) CA3128743C (https=)
MX (1) MX392849B (https=)
WO (1) WO2017173024A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
JP2019513137A (ja) 2016-03-30 2019-05-23 アユヴィス リサーチ インク．Ａｙｕｖｉｓ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 新規組成物及び治療方法
US20220143059A1 (en) * 2016-03-30 2022-05-12 Ayuvis Research, Inc. Compositions and therapeutic methods
US12594286B2 (en) 2018-07-02 2026-04-07 Ayuvis Research, Inc. Immunodulating small molecules
KR20210027381A (ko) * 2018-07-02 2021-03-10 아유비스 리서치, 인코포레이티드 신규 면역조절 소분자
EP3820512B1 (en) * 2018-07-02 2024-04-24 Ayuvis Research, Inc. Immunomodulating compositions comprising oligosaccharide derivatives
JP7382281B2 (ja) * 2020-05-25 2023-11-16 株式会社東海理化電機製作所 制御装置および制御方法
JP7382280B2 (ja) 2020-05-25 2023-11-16 株式会社東海理化電機製作所 制御装置および制御方法
WO2022169855A1 (en) * 2021-02-04 2022-08-11 Ayuvis Research, Inc. Chitin analogs for the treatment of kidney diseases
US12440471B2 (en) * 2021-07-30 2025-10-14 Ayuvis Research, Inc. Compositions and methods for the treatment of bronchopulmonary dysplasia (BPD) and BPD-associated pulmonary hypertension
WO2023086877A1 (en) * 2021-11-12 2023-05-19 Ayuvis Research, Inc. Novel compositions and therapeutic methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570682A1 (en) * 1992-05-07 1993-11-24 American Cyanamid Company Synthetic lipid A glycoconjugate antigens for use in vaccines

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4152413A (en) 1978-08-18 1979-05-01 Chromalloy American Corporation Oral vaccine for swine dysentery and method of use
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US4621075A (en) 1984-11-28 1986-11-04 The Procter & Gamble Company Gel-form topical antibiotic compositions
CA1261264A (en) 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
JPH0615476B2 (ja) * 1985-05-22 1994-03-02 イハラケミカル工業株式会社 抗感染症剤
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
FR2640627A1 (fr) * 1988-12-16 1990-06-22 Commissariat Energie Atomique Nouveaux fluorures d'aldosaminyle, leur preparation et leur utilisation pour la fabrication d'oligosaccharides amines lies (1 -> 4)
US5932640A (en) 1989-01-21 1999-08-03 Clariant Finance (Bvi) Limited Dyeability or mass coloration of synthetic polyamide
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
JPH041115A (ja) 1990-04-13 1992-01-06 Pola Chem Ind Inc 皮膚外用剤
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
AU7484198A (en) 1997-05-12 1998-12-08 Sage Pharmaceuticals, Inc. Topical spray for burn treatment and anti-infection
US6492350B2 (en) 2000-01-27 2002-12-10 Jdc (Hawaii) Inc. Chitin oligosaccharides and/or chitosan oligosaccharides for preventing or treating common cold or treating pain
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US7098195B2 (en) * 2001-11-28 2006-08-29 Health Research, Inc. Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells
EP1455835A2 (en) * 2001-12-13 2004-09-15 ISM Biopolymer Inc. Method of modulating release of saccharides and uses thereof
AU2003211574A1 (en) * 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US7632654B2 (en) * 2002-04-29 2009-12-15 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Means and methods for detecting endoglycosidase activity
EP1440683A1 (de) 2003-01-23 2004-07-28 Cognis France S.A. Verwendung von Oligoglucosaminen in kosmetischen oder dermatologischen Zubereitungen
CA2428744C (en) 2003-01-24 2013-06-25 University Of Manitoba Inhibition of lysozyme in treating sepsis-induced myocardial dysfunction
US20050255048A1 (en) 2004-05-15 2005-11-17 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
JP5035787B2 (ja) 2005-10-04 2012-09-26 焼津水産化学工業株式会社 α−１、４結合型Ｎ−アセチルグルコサミン含有Ｏ−グリカン型糖鎖の分泌促進剤並びにこれを含有するヘリコバクターピロリ菌を原因とする病態の治療予防剤
FR2892419A1 (fr) * 2005-10-24 2007-04-27 Univ Claude Bernard Lyon I Eta Heteroligomeres de d-glucasamine et n-acetyl-d-glucosamine, leur procede de preparation et leur utilisation
JP5140246B2 (ja) * 2006-03-15 2013-02-06 公益財団法人野口研究所 Ｎ−アセチルグルコサミンの誘導体を含有するピロリ菌増殖抑制剤
GB0622688D0 (en) * 2006-11-14 2006-12-27 Diosamine Dev Corp Novel compounds
ES2543063T3 (es) * 2008-05-16 2015-08-14 Galecto Biotech Ab Nueva síntesis de inhibidores de galactósidos
CN101732338A (zh) 2008-11-26 2010-06-16 中国科学院大连化学物理研究所 壳六糖在制备预防血管生成的药物中的应用
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
CN102475714A (zh) 2010-11-29 2012-05-30 中国科学院大连化学物理研究所 壳寡糖单一化合物在免疫增强药物中的应用
WO2012129802A1 (en) * 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof
EP2885323B1 (en) 2012-08-17 2023-08-30 The University of North Carolina At Chapel Hill Water soluble nitric oxide-releasing polyglucosamines and uses thereof
EP3001838A4 (en) 2013-05-14 2017-02-08 Medlmmune, LLC Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses therof
JP2019513137A (ja) 2016-03-30 2019-05-23 アユヴィス リサーチ インク．Ａｙｕｖｉｓ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 新規組成物及び治療方法
JP7246205B2 (ja) * 2019-02-27 2023-03-27 センクシア株式会社 デッキプレート

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570682A1 (en) * 1992-05-07 1993-11-24 American Cyanamid Company Synthetic lipid A glycoconjugate antigens for use in vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ekborg G. et al., Note p-(Trifluoroacetamido)phenyl-2-acetamido-2-deoxy-4-O-β-D-mannopyranosyl-β-D-glucopyranoside, Carbohydrate Research, 1984, 129, pages 287-292 *

Also Published As

Publication number Publication date
EP3436467B1 (en) 2025-08-06
JP7594268B2 (ja) 2024-12-04
EP3436467A4 (en) 2020-03-18
JP7774885B2 (ja) 2025-11-25
CA3015494C (en) 2021-10-26
JP7357364B2 (ja) 2023-10-06
JP2020193215A (ja) 2020-12-03
MX2018009802A (es) 2018-12-06
AU2017244114A1 (en) 2018-11-08
KR20210122865A (ko) 2021-10-12
MX392849B (es) 2025-03-24
JP2020090675A (ja) 2020-06-11
CN108884121A (zh) 2018-11-23
AU2023222844A1 (en) 2023-09-14
KR20180125583A (ko) 2018-11-23
AU2021232715A1 (en) 2021-10-14
BR112018067833A2 (pt) 2019-03-19
CA3015494A1 (en) 2017-10-05
US11207343B2 (en) 2021-12-28
JP2023179505A (ja) 2023-12-19
US20170281667A1 (en) 2017-10-05
EP3436467C0 (en) 2025-08-06
CA3128743A1 (en) 2017-10-05
CN108884121B (zh) 2022-05-31
BR112018067833B1 (pt) 2024-03-05
AU2025205307A1 (en) 2025-07-31
JP2019513137A (ja) 2019-05-23
CN114712383A (zh) 2022-07-08
CA3128743C (en) 2024-06-25
CN114712383B (zh) 2024-09-24
KR102532825B1 (ko) 2023-05-17
EP3436467A1 (en) 2019-02-06
JP2024041834A (ja) 2024-03-27
KR102306956B1 (ko) 2021-10-01
WO2017173024A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
AU2017244114B2 (en) Novel compositions and therapeutic methods
ES2214543T3 (es) Liposacaridos sustituidos utiles en el tratamiento y prevencion de la endotoxemia.
US11364253B2 (en) Immunodulating small molecules
JP7805288B2 (ja) 操作された細胞及びその使用
HK40004181A (en) Beta-anomer-saccharides for use in the treatment of sepsis, septic shock, septicemia, burn or wound infection
HK40004181B (en) Beta-anomer-saccharides for use in the treatment of sepsis, septic shock, septicemia, burn or wound infection
US20220143059A1 (en) Compositions and therapeutic methods
WO2023086877A1 (en) Novel compositions and therapeutic methods
US20230000887A1 (en) Novel Immunodulating Small Molecules
EP4531867A1 (en) Novel immunodulating small molecules

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)